Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dose Level 1-Baylor College of Medicine-chronic lymphocytic leukemia
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**Dose Level 1-Baylor College of Medicine-chronic lymphocytic leukemia** was the lowest-dose cohort of the CLIPA Phase I investigational autologous cellular cancer-vaccine program for chronic lymphocytic leukemia. The treatment used a subcutaneous mixture of a fixed dose of **2 × 10^7 IL-2-secreting autologous B-CLL cells** with **2 × 10^5 CD40L-expressing autologous B-CLL cells** per injection. The patient-derived leukemia cells were genetically modified ex vivo to provide local interleukin-2 signaling and CD40 ligand-mediated activation of CD40 on leukemia cells, increasing expression of co-stimulatory molecules including CD80 and CD86 and promoting anti-leukemia cytotoxic T-cell responses.
- Other names
- IL-2-secreting CD40L-expressing autologous B-CLL cellsIL2-secreting CD40L-expressing autologous B-CLL cellsIL 2-secreting CD40L-expressing autologous B-CLL cells
02
Targets
CD40 (Cluster of differentiation 40 receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on Dose Level 1-Baylor College of Medicine-chronic lymphocytic leukemia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dose Level 1-Baylor College of Medicine-chronic lymphocytic leukemia.